siadh การใช้

• SIADH in turn can be caused by a number of problems.
• The cornerstone of therapy for SIADH is reduction of water intake.
• In SIADH, vasopressin release is not fully suppressed, despite hypotonicity.
• Alternatively, they may have the Syndrome of Inappropriate ADH ( SIADH ).
• SIADH was first described in 1957.
• Ectopic production of large amounts of ADH leads to syndrome of inappropriate antidiuretic hormone hypersecretion ( SIADH ).
• Other paraneoplastic syndromes include hypercalcemia, SIADH, Cushing's syndrome and a variety of neurological disorders.
• SIADH can also be treated with specific antagonists of the ADH receptors, such as conivaptan or tolvaptan.
• These have been used in clinical trials as a treatment for syndrome of inappropriate antidiuretic hormone ( SIADH ).
• Some forms of cancer can cause SIADH, particularly small cell lung carcinoma but also a number of other tumors.
• Most cases of hyponatremia in children are caused by appropriate secretion of antidiuretic hormone rather than SIADH or another cause.
• Electrolyte disturbances such as low blood sodium may be seen due to SIADH when the hypothalamus is involved in the disease process.
• SIADH is therefore primarily a condition that results in the abnormal handling of water loading and not a problem with excessive solute loss.
• It has been suggested that abnormalities in such secretin release could explain the abnormalities underlying type D syndrome of inappropriate antidiuretic hormone hypersecretion ( SIADH ).
• SIADH is less common than appropriate release of ADH . While it should be considered in a differential, other causes should be considered as well.
• While SIADH has been described primarily with higher doses of cyclophosphamide, it can also occur with the lower doses used in the management of inflammatory disorders.
• The first step is a clinical evaluation Biochemical tests may reveal hyponatremia and the other features of SIADH . Relevant supplementary tests are listed in table 1.
• In SIADH, the release of ADH is not inhibited by a reduction in plasma osmolality when the individual ingests water and the osmolality of the plasma drops.
• Demeclocycline has since been the drug of choice for treating SIADH, although it may be superseded as vasopressin receptor antagonists, such as tolvaptan, become available.
• The water retention causes hyponatremia, which is a key feature in SIADH . This is purely a problem of water metabolism with no abnormalities in total body sodium metabolism.